Literature DB >> 19013431

Hypoxia-inducible factor 1alpha is deregulated by the serum of rats with adjuvant-induced arthritis.

Hye-Lim Kim1, Young-Suk Cho, Hong Choi, Yang-Sook Chun, Zang Hee Lee, Jong-Wan Park.   

Abstract

Rheumatoid arthritis (RA) is known to be associated with increased risks of hypoxia-related diseases, whose progresses are critically determined by HIF-1alpha. The authors hypothesized that the hypoxia-related complications of RA are associated with HIF-1alpha deregulation by some factor(s) in RA serum. Arthritis was induced in female Lewis rats by injecting complete Freund's adjuvant. The effects of arthritic rat serum (ARS) on hypoxic responses were investigated by incubating Hep3B cells in ARS. In the presence of ARS, HIF-1alpha was down-regulated and inactivated under hypoxic conditions. ARS inactivated AKT and mTOR, which led to impaired HIF-1alpha protein synthesis. Furthermore, insulin was found to be deficient in ARS and insulin supplementation fully recovered HIF-1alpha synthesis with AKT and mTOR activation. These results suggest that HIF-1alpha deregulation by components in serum is responsible for the RA-associated aggravation of hypoxic diseases in extra-articular tissues.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19013431     DOI: 10.1016/j.bbrc.2008.11.013

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  2 in total

1.  Insulin-like growth factor and epidermal growth factor treatment: new approaches to protecting steatotic livers against ischemia-reperfusion injury.

Authors:  Araní Casillas-Ramírez; Amine Zaouali; Susagna Padrissa-Altés; Ismail Ben Mosbah; Anna Pertosa; Izabel Alfany-Fernández; Maria Bintanel-Morcillo; Carme Xaus; Antoni Rimola; Juan Rodés; Joan Roselló-Catafau; Carmen Peralta
Journal:  Endocrinology       Date:  2009-03-12       Impact factor: 4.736

Review 2.  The role of hypoxia in inflammatory disease (review).

Authors:  John Biddlestone; Daniel Bandarra; Sonia Rocha
Journal:  Int J Mol Med       Date:  2015-01-27       Impact factor: 4.101

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.